Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
davalintide
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Davalintide is a second-generation, 32-amino acid peptide analogue of human amylin developed by Amylin Pharmaceuticals for the treatment of obesity. It acts as an amylin mimetic with enhanced pharmacological properties compared to native amylin. Davalintide binds with high affinity to amylin receptors (as well as calcitonin and calcitonin gene-related peptide receptors), resulting in slowed gastric emptying, inhibition of digestive secretions (gastric acid, pancreatic enzymes, bile), reduced glucagon secretion, and increased satiety. These actions contribute to antihyperglycemic effects and weight loss through decreased food intake and fat-specific weight reduction while sparing lean mass. The drug was investigated in clinical trials for obesity but development was discontinued around 2010[2][3][4][5].
- Other names
- davalintide
02
Targets
AMY receptor (Calcitonin receptor (with ramps))Calcitonin gene-related peptide type 1 receptorCALCR (Calcitonin receptor)
Beyond the preview
Go deeper on davalintide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on davalintide.